Oncotarget

Research Papers:

A Robust Approach to Enhance Tumor-selective Accumulation of Nanoparticles

Yuan Qiao, Xin Huang, Sridhar Nimmagadda, Renyuan Bai, Verena Staedtke, Catherine A. Foss, Ian Cheong, Matthias Holdhoff, Yoshinori Kato, Martin G. Pomper, Gregory J. Riggins, Kenneth W. Kinzler, Luis A. Diaz, Bert Vogelstein, Shibin Zhou _

PDF |  Full Text  |  Supplementary Files  |  Author Information


Abstract

Yuan Qiao1*, Xin Huang1*, Sridhar Nimmagadda2*, Renyuan Bai3*, Verena Staedtke3, Catherine A. Foss2, Ian Cheong1, Matthias Holdhoff1, Yoshinori Kato2, Martin G. Pomper2, Gregory J. Riggins3, Kenneth W. Kinzler1, Luis A. Diaz, Jr1, Bert Vogelstein1, Shibin Zhou1

1The Ludwig Center for Cancer Genetics and Therapeutics, Howard Hughes Medical Institute and Sidney Kimmel Cancer Center at the Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA

2Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA

3Department of Neurosurgery, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA

*These authors contributed equally to this work

Keywords: Tumor, Vasculature, Nanoparticle, Inflammation, TNF-α

Received: February 28, 2011; Accepted: March 1, 2011; Published: March 1, 2011;

Correspondence:

Shibin Zhou, e-mail:

Abstract

While nanoparticles have shown great promise as drug carriers in cancer therapy, their effectiveness is critically dependent on the structural characteristics of the tumor vasculature. Here we demonstrate that several agents capable of inducing vascular responses akin to those observed in inflammatory processes enhance the accumulation of nanoparticles in tumors. The vascular-active agents tested in this study included a bacterium, a pro-inflammatory cytokine, and microtubule-destabilizing drugs. Using radiolabeled nanoparticles, we show that such agents can increase the tumor to blood ratio of radioactivity by more than 20-fold compared to nanoparticles alone. Moreover, vascular-active agents dramatically improved the therapeutic effect of nanoparticles containing radioactive isotopes or chemotherapeutic agents. This resulted in cures of animals with subcutaneous tumors and significantly prolonged the survival of animals with orthotopic brain tumors. In principle, a variety of vascular-active agents and macromolecular anticancer formulations can be combined, which makes this approach broadly applicable and particularly suited for the treatment of patients who have failed standard therapies.

Author Information

Yuan Qiao
The Ludwig Center for Cancer Genetics and Therapeutics, Howard Hughes Medical Institute and Sidney Kimmel Cancer Center at the Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA

Xin Huang
The Ludwig Center for Cancer Genetics and Therapeutics, Howard Hughes Medical Institute and Sidney Kimmel Cancer Center at the Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA.

Sridhar Nimmagadda
Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA

Renyuan Bai
Department of Neurosurgery, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA

Verena Staedtke
Department of Neurosurgery, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA

Catherine A. Foss
Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA

Ian Cheong
The Ludwig Center for Cancer Genetics and Therapeutics, Howard Hughes Medical Institute and Sidney Kimmel Cancer Center at the Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA.

Matthias Holdhoff
The Ludwig Center for Cancer Genetics and Therapeutics, Howard Hughes Medical Institute and Sidney Kimmel Cancer Center at the Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA.

Yoshinori Kato
Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA

Martin G. Pomper
Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA

Gregory J. Riggins
Department of Neurosurgery, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA

Kenneth W. Kinzler
The Ludwig Center for Cancer Genetics and Therapeutics, Howard Hughes Medical Institute and Sidney Kimmel Cancer Center at the Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA.

Luis A. Diaz
The Ludwig Center for Cancer Genetics and Therapeutics, Howard Hughes Medical Institute and Sidney Kimmel Cancer Center at the Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA.

Bert Vogelstein
The Ludwig Center for Cancer Genetics and Therapeutics, Howard Hughes Medical Institute and Sidney Kimmel Cancer Center at the Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA.

Shibin Zhou
Primary Contact  _

The Ludwig Center for Cancer Genetics and Therapeutics, Howard Hughes Medical Institute and Sidney Kimmel Cancer Center at the Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 227


Copyright © Impact Journals LLC 2008